Lidocaína Medinfar

Lidocaine Hydrochloride, the active ingredient in Lidocaína Medinfar, is a local anesthetic presented as a sterile solution for subcutaneous use. It is employed to produce reversible loss of sensation in minor surgical or diagnostic procedures and to relieve pain in subcutaneous tissue in adult patients.

GNH USA supplies Lidocaína Medinfar as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide, with distribution aligned to EU quality standards and supporting clinical needs across diverse therapeutic settings.

Lidocaine Hydrochloride is a local anesthetic that blocks nerve conduction in peripheral tissues.

- Minor surgical procedures: provides local anesthesia to facilitate painless incision and manipulation. - Diagnostic procedures: enables pain‑free needle insertion or tissue sampling. - Subcutaneous pain relief: reduces discomfort in superficial tissue injuries or injections.

Adverse reactions to Lidocaína Medinfar may vary in frequency and severity.

Common Side Effects: - Injection site pain: mild discomfort at the site of administration. - Redness or swelling: localized erythema or edema. - Tingling sensation: transient paresthesia near the injection area. - Nausea: occasional mild nausea.

Serious or Rare Side Effects: - Allergic reaction: urticaria, angioedema, or anaphylaxis. - Cardiovascular effects: hypotension, bradycardia, or arrhythmia. - Central nervous system toxicity: seizures or loss of consciousness (rare).

When using Lidocaína Medinfar, consider the following precautions to ensure safe administration.

- Patient allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics. - Cardiovascular status: avoid use in patients with severe heart block or uncontrolled arrhythmias. - Dosage limits: adhere to recommended maximum dose to prevent systemic toxicity. - Concomitant CNS depressants: monitor if used with other agents that lower seizure threshold. - Pregnancy and lactation: use only if benefit outweighs potential risk, as safety data are limited. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Lidocaína Medinfar may interact with other medicines; awareness of significant interactions helps prevent adverse events.

Major Interactions (Avoid): - Class I antiarrhythmic drugs (e.g., quinidine, procainamide): may increase lidocaine plasma levels and risk of toxicity. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can reduce metabolism, raising systemic exposure.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may potentiate cardiovascular depressant effects. - CNS depressants (e.g., benzodiazepines, opioids): may enhance central nervous system toxicity. - Other local anesthetics: cumulative dosing can increase risk of systemic toxicity.